New cancer drug candidate SHR-4685 enters first human tests

NCT ID NCT07676903

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called SHR-4685 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 170 adults aged 18 to 75 with measurable tumors and good organ function are eligible to join.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

SHR-4685

What this could lead to

If safe and effective, SHR-4685 could become a new treatment option for people with advanced solid tumors.

What could go wrong

This is a very early Phase 1 trial focused on safety and dosing, not yet on effectiveness. Many drugs fail at this stage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, 100142, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact